Corriente Advisors, LLC Reata Pharmaceuticals Inc Transaction History

Corriente Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $7.11 Million - $10.2 Million	-71,115 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $5.57 Million - $10.8 Million	71,115 New	71,115 $10.1 Million
Q1 2021 May 18, 2021	SELL	$94.25 - $132.81 $49.5 Million - $69.7 Million	-525,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $23 Million - $41.5 Million	225,000 Added 75.0%	525,000 $64.9 Million
Q3 2020 Nov 03, 2020	BUY	$93.53 - $163.34 $14.3 Million - $24.9 Million	152,500 Added 103.39%	300,000 $29.2 Million
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $5.37 Million - $7.5 Million	-42,500 Reduced 22.37%	147,500 $23 Million
Q1 2020 May 18, 2020	SELL	$124.16 - $247.74 $248,320 - $495,480	-2,000 Reduced 1.04%	190,000 $27.4 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $14.3 Million - $41.8 Million	192,000 New	192,000 $39.3 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Corriente Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Corriente Advisors, LLC with notifications on news.